[Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma].

Twenty-nine transplant eligible newly diagnosed multiple myeloma (NDMM) patients have received Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) as induction treatment in our institute since November 2011. CyBorD is composed of CPA 300 mg/m2 p.o., Bor 1.3 mg/m2 i.v. or s.c., and Dex 40 mg/body p.o. on days 1, 8, 15, and 22. The median number of CyBorD cycles was 4 (range 2-6), except in one patient who progressed during the first cycle. Grade 4 neutropenia was observed in 2 patients, but none experienced grade 2 thrombocytopenia. Grade 3 non-hematologic adverse events were observed in two patients with varicella-zoster virus reactivation. Responses after CyBorD were ≥PR in 72%, ≥VGPR in 52%, ≥CR in 21%, and sCR in 21%. Autologous stem cells were harvested in 27 patients. Seventeen of these 27 patients received high-dose melphalan and autologous stem cell transplantation (ASCT) within 12 months after diagnosis. Patients with ≥CR increased to 59% after ASCT. Our data suggest the efficacy and the feasibility of administering CyBorD to transplant eligible NDMM patients.